Biobehavioral Cancer Control (BCC) Recognizing the importance of research focused on the person in whom cancer develops and is treated, as well as on the tumor itself, Hillman Cancer Center (HCC) has included a program focused on behavioral issues in oncology since its inception in 1985. The overarching goal of the Biobehavioral Cancer Control (BCC) Program is to reduce the burden of cancer across all phases of the cancer control continuum, from cancer risk through cancer survivorship, via research centered on behavioral factors and the patient/person experience. Grounded in the behavioral sciences, program investigators conduct preclinical, translational, and clinical research studies (including randomized interventional trials) that are largely encompassed by two central themes: (1) Cancer risk reduction focuses on behavioral factors known to contribute to cancer risk, particularly tobacco use and the biobehavioral mechanisms underlying the initiation, maintenance and cessation of tobacco use; and (2) Cancer survivorship focuses on characterization of disease and treatment- related symptoms in cancer survivors, the biobehavioral mechanisms underlying those symptoms, and personalized management strategies to prevent or reduce cancer and cancer therapy-related symptoms and improve outcomes. BCC is a highly transdisciplinary program with a strong track record of research productivity as evidenced by publications and grant support. Under the leadership of Catherine Bender, PhD, RN and Dana Bovbjerg, PhD, BCC has 45 members representing 15 departments and 6 schools within the University of Pittsburgh. BCC members conduct cancer-focused research supported by $5.4M in total annual direct funding of which $3.3M is NCI funding, $2.0M is other peer-reviewed and $0.1M is non-peer-reviewed. A return of $3.2M was obtained on investment of $251K of CCSG developmental funds. From 2015-2019, BCC members published 493 cancer-related publications representing 17% intra-programmatic, 16% inter- programmatic, and 58% inter-institutional collaborations. Consistent with HCC?s overall strategic plan and the cancer challenges of our catchment area, the specific aims of BCC are to: (a) investigate behavioral factors known to contribute to cancer risk reduction, with a particular focus on biobehavioral mechanisms underlying initiation, maintenance, and cessation of tobacco use (Theme 1); (b) develop and test innovative biobehavioral interventions to reduce cancer risk behaviors with a particular emphasis on tobacco use and cancer prevention behaviors (Theme 1); (c) characterize disease and treatment-related symptoms in cancer survivors including the biobehavioral mechanisms underlying those symptoms (Theme 2); and (d) develop and test personalized management strategies to prevent or reduce cancer and cancer therapy-related symptoms and improve adherence to therapy, quality of life, and functional ability of cancer survivors (Theme 2).
These aims will be addressed with key HCC support for BCC research activities at both strategic and logistical levels.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA047904-32
Application #
10024351
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-09-10
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
32
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15260
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Lontos, Konstantinos; Tsagianni, Anastasia; Yuan, Jian-Min et al. (2018) Location matters in early stage nodal diffuse large B-cell lymphoma. Leuk Lymphoma :1-4

Showing the most recent 10 out of 1187 publications